The Zacks Analyst Blog Highlights AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market

18.10.24 15:38 Uhr

Werte in diesem Artikel
Aktien

156,58 EUR -0,60 EUR -0,38%

198,06 EUR 1,06 EUR 0,54%

282,20 EUR -1,80 EUR -0,63%

44,65 USD 0,92 USD 2,10%

28,60 EUR -1,40 EUR -4,67%

Indizes

PKT PKT

20.684,6 PKT 145,4 PKT 0,71%

18.987,5 PKT 195,7 PKT 1,04%

2.863,5 PKT 16,9 PKT 0,59%

5.917,0 PKT 23,4 PKT 0,40%

For Immediate ReleaseChicago, IL – October 18, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Automatic Data Processing, Inc. ADP, Analog Devices, Inc. ADI, Taylor Devices, Inc. TAYD and Village Super Market, Inc. VLGEA.Here are highlights from Thursday’s Analyst Blog:Top Stock Reports for AbbVie, ADP and Analog DevicesThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Automatic Data Processing, Inc. and Analog Devices, Inc, as well as two micro-cap stocks Taylor Devices, Inc. and Village Super Market, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>AbbVie's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+27.4% vs. +22.8%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq. Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, which should support top-line growth in the next few years.AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025. AbbVie has been on an acquisition spree lately in its core space of immunology.However, the company faces several near-term headwinds like Humira's biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth trend for fillers in the U.S. and China. Estimate movements have been mixed ahead of Q3 results.(You can read the full research report on AbbVie here >>>)Shares of ADP have outperformed the Zacks Outsourcing industry over the year-to-date period (+26.8% vs. +24.4%). The company continues to enjoy a dominant position in the human capital management market through strategic buyouts like Celergo, WorkMarket, Global Cash Card and The Marcus Buckingham Company.ADP is focused on delivering a complete suite of cloud-based HCM and HR Outsourcing solutions. Further, it continues to innovate, improve operations and invest in its transformation efforts.On the flip side, ADP faces significant competition in each of its product lines. The company's failure to remain technologically updated might reduce the demand for its solutions and services. Rising expenses due to investment in transformation efforts remain concerning.(You can read the full research report on ADP here >>>)Analog Devices' shares have outperformed the Zacks Semiconductor - Analog and Mixed industry over the year-to-date period (+16.1% vs. +6.6%). The company is benefiting from strong momentum across the automotive end market. Strong momentum across electric vehicle space on the back of its robust Battery Management System solutions remains a tailwind.Strong investments in technology and business innovation are contributing well. Increasing power design wins is another positive. The solid momentum of the HEV platform across cabin electronics ecosystem is positive.Nonetheless, Analog Devices is suffering from softness in the consumer market. The weak demand environment remains a major concern. The sluggish communications market, due to the broad-based inventory corrections, is a major negative. The ongoing inventory correction is expected to be a headwind for the company in the near term. Broad-based weakness in the industrial end-market remains a headwind.(You can read the full research report on Analog Devices here >>>)Shares of Taylor Devices have outperformed the Zacks Manufacturing - General Industrial industry over the year-to-date period (+123.9% vs. +11.9%). This microcap company with market capitalization of $154.53 million posted robust first-quarter fiscal 2025 results, with revenues rising 17% to $11.6 million and gross margins expanding from 44% to 47%, driven by improved pricing and efficiencies. Net income surged 44% to $2.7 million, reflecting scale benefits and disciplined expense control despite an 8% rise in SG&A from compensation costs.Aerospace and defense, accounting for 59% of sales, grew 20%, supported by legacy contracts and new programs, providing resilience in uncertain markets. Geographic diversification, with Asian sales up 38%, and a $28.4 million backlog, offers revenue visibility. Strong liquidity, including $2.2 million in cash and $25 million in short-term investments, ensures growth capacity.However, working capital constraints are emerging. Structural segment sales dropped from 35% to 29%, reflecting slowing infrastructure demand. Persistently rising SG&A costs could pressure margins.(You can read the full research report on Taylor Devices here >>>)Village Super Market's shares have gained +22.1% over the year-to-date period against the Zacks Retail - Supermarkets industry's gain of +53.5%. This microcap company with market capitalization of $456.67 million have acquired strategic stake of 12.8% in Wakefern Food Corp provides a competitive edge in purchasing, distribution, and technology, benefiting from scale economies usually reserved for larger chains.The use of recognized brands like ShopRite, Fairway, and Gourmet Garage adds brand equity, while shared marketing through Wakefern helps reduce costs. In fiscal 2024, Village grew sales by 3.2% to $2.24 billion, driven by digital growth. A $75 million capital plan aims to expand its 34 supermarkets and three specialty markets, enhancing its market presence.Village Super Market is also advancing its e-commerce capabilities to capture rising demand for online grocery shopping. Despite its strong liquidity position, Village faces competitive pressure from larger chains and online platforms, rising labor costs, and operational risks tied to its regional concentration. Rising lease obligations adds financial strain.(You can read the full research report on Village Super Market here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                      https://www.zacks.com                                                   Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Analog Devices, Inc. (ADI): Free Stock Analysis Report Automatic Data Processing, Inc. (ADP): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Village Super Market, Inc. (VLGEA): Get Free Report Taylor Devices, Inc. (TAYD): Get Free ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf AbbVie

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AbbVie

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu AbbVie Inc

Analysen zu AbbVie Inc

DatumRatingAnalyst
27.06.2019AbbVie Peer PerformWolfe Research
29.04.2019AbbVie Market PerformBMO Capital Markets
26.12.2018AbbVie BuyStandpoint Research
02.02.2018AbbVie UnderperformBMO Capital Markets
25.09.2017AbbVie NeutralUBS AG
DatumRatingAnalyst
29.04.2019AbbVie Market PerformBMO Capital Markets
26.12.2018AbbVie BuyStandpoint Research
23.10.2015AbbVie BuyUBS AG
17.04.2015AbbVie OutperformBMO Capital Markets
06.01.2015AbbVie BuyUBS AG
DatumRatingAnalyst
27.06.2019AbbVie Peer PerformWolfe Research
25.09.2017AbbVie NeutralUBS AG
15.03.2016AbbVie HoldDeutsche Bank AG
01.12.2015AbbVie Equal WeightBarclays Capital
DatumRatingAnalyst
02.02.2018AbbVie UnderperformBMO Capital Markets

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AbbVie Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"